In patients with type 2 diabetes and cirrhosis, SGLT2 inhibitors show increased efficacy over DPP-4 inhibitors in kidney, cardiac, and liver outcomes.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/sglt2-inhibitors-show-cardiorenal-liver-benefits-cirrhosis-2026a1000a7n?src=rss
Author :
Publish date : 2026-04-03 10:26:00
Copyright for syndicated content belongs to the linked Source.
